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Pleural adhesiolysisAbstract Background: In dealing with septated pleural effusion, intrapleural ﬁbrinolytics may be
a useful alternative for others such as use of video assisted thoracic surgery or the conventional tho-
racotomy. The use of intrapleural ﬁbrinolytics may be a safer, easier and cost effective management
option that can promote pleural ﬂuid drainage.
Objective: To evaluate the role of intrapleural streptokinase as a ﬁbrinolytic agent in the
management of pleural effusion with adhesions.
Patients and methods: This study was designed as a case series study in a prospective manner.
Twenty-ﬁve patients were included in the study. All were admitted at Chest Department, Assiut
University Hospital .The study was conducted during the period between September 2013 and
September 2014. All patients had septated pleural effusion; candidate for drainage with failure of
satisfactory pleural ﬂuid drainage 24 h following intercostal tube (ICT) placement provided that
the tube was properly positioned and not obstructed. Streptokinase was given daily at a dose of
250,000 IU dissolved in 40 ml of normal saline instilled in the pleural cavity through the chest tube.
Instillation was repeated as long as no serious complication occurred and the drained ﬂuid volume
was >100 cc with a maximum of 14 doses. Patients were assessed by the amount of drainage
through intercostal drain, chest X-ray and chest ultrasound. Also patients were assessed carefully
for evidence of complications.
Results: The study revealed increased drainage of pleural ﬂuid through intercostal tube after
streptokinase instillation. The observation difference in ﬂuid volume before and after streptokinase
instillation is found to be highly signiﬁcant statistically (p< 0.001) .Outcome was deﬁned according
to scoring of changes in X-ray and ultrasound with success rate of 60%. Chance of success increases
when the adhesions are ﬁne based on the sonographic features. No major adverse effects were noted.
Conclusion: We conclude that intrapleural streptokinase therapy may be considered in septated
pleural effusion as a safe and effective treatment; it may obviate the need for surgery.
Also, the ultrasound echo features of adhesions could be considered as a predictor for the response.
ª 2015 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Septated pleural effusions are those with ultrasound evidence
of ﬁbrin strands or septa ﬂoating inside the pleural space [1].
Intrapleural adhesions and septated effusions remain a com-
mon and burdensome clinical entity. The presence of adhe-
sions carries a poor prognostic factor in patients with
exudative pleural effusions and may render the pleural ﬂuid
drainage difﬁculty [2]. In dealing with this problem, intrapleu-
ral ﬁbrinolytics may be a safe, easy, cost effective management
option. Also, it may be a useful alternative for others such as
use of video assisted thoracic surgery or the conventional tho-
racotomy [3]. The purpose of our study was to assess the safety
and efﬁcacy of streptokinase (SK) for intrapleural ﬁbrinolysis
in patients with septated pleural effusion.
Patients and methods
This study was designed as a case series study in a prospective
manner. Twenty-ﬁve patients having septated pleural effusion
were included in the study. All were admitted at Chest
Department, Assiut University Hospital .The study was con-
ducted during the period between September 2013 and
September 2014.
Inclusion criteria
Patients who fulﬁlled all of the following criteria were
included:
1 – Patient had pleural effusion with known underlying
etiology.
2 – Presence of intrapleural adhesions as documented
sonographically.
3 – Pleural ﬂuid drainage was indicated.
4 – Difﬁcult thoracentesis.
5 – Failure of satisfactory pleural ﬂuid drainage 24 h
following intercostal tube (ICT) placement provided that
the tube was properly positioned and not obstructed.
6 – Patient agreed to contribute in this study.
Exclusion criteria
Patient was excluded from this study if one of the following
was met:
1 – Recent severe trauma, hemorrhage, or stroke.
2 – Patient had bleeding disorder.
3 – Patient maintained on anticoagulant therapy.
4 – Patient had history of streptokinase (SK) administra-
tion in the previous 2 years.
The following were done before starting the treatment protocol
1 – A full history was taken and clinical examination was
performed.
2 – Coagulation proﬁle.
3 – X-ray and ultrasound evaluation of the chest.Treatment protocol
All patients initially had a closed I.C.T drainage with a size
24–32 Fr. The chest tube is placed under the water seal system.
The ﬁrst dose of ﬁbrinolytic therapy started 24 h after ICT
placement. For intrapleural ﬁbrinolysis, no premedications or
analgesics were administered systemically or intrapleurally.
Streptokinase was used at a dose of 250,000 IU dissolved in
40 ml of normal saline instilled in the pleural cavity through
the chest tube. Patient was placed in the lateral decubitus posi-
tion with the unaffected lung dependent during agent instilla-
tion, to be sure that all of this agent drained from the chest
catheter into the treated pleural cavity. The tube is then
clamped for 2–4 h and patient asked to repeatedly change posi-
tion so that streptokinase could thoroughly spread in pleural
cavity. Patient remained in bed until the tube was unclamped,
to minimize the amount of agent that might leak out around
the tube thereby decreasing its effective dwell time in the pleural
cavity. Our plan during protocol application was to stop fur-
ther instillation if severe complication occurred and if drained
ﬂuid through the tube was <100 cc in 24 h provided that tube
is patent and properly positioned. Also, we planned to continue
the daily instillation as long as the drained ﬂuid volume is
>100 cc with a maximum of 14 doses according to Maskell
et al. [4]. Data about Volume of pleural ﬂuid drained from
the chest tube before and after streptokinase instillation were
collected daily. Chest X-ray and chest ultrasound were per-
formed daily till discharging day. Total dose of SK and number
of instillations during the course of therapy were recorded.
The effectiveness of the protocol was assessed by
1 – Monitoring the volume of ﬂuid drained from the chest
tube daily.
2 – Chest ultrasound to check dissolution of adhesions.
3 – Chest radiography to see radiological clearance.Evaluation of pleural effusion on discharging day by chest X-ray
was described as
0 – No change.
1 – Less than 1/3 improvement.
2 – Improvement between 1/3 and 2/3.
3 – More than 2/3 improvement without complete
clearance.
4 – Complete radiological clearance.Regarding the evaluation by chest US, four results were recorded
on discharge
0 – No change.
1 – Dissolution of adhesions in some regions.
2 – Dissolution of adhesions in all regions with residual
pleural lesion.
3 – Total adhesion dissolution without residual pleural
lesion.
Residual pleural lesion means pleural ﬁbrosis, nodules or
masses.








Range (day) Mean + SD
Duration of illness 10.0–90.0 31.3 + 7.7
Table 2 Etiological diagnosis of pleural effusion in the
studied patients (n= 25).
Diagnosis Number of patients (%)
Empyema 9 (36%)
Para pneumonic eﬀusion 7 (28%)
Malignant eﬀusion 6 (24%)
Tuberculous eﬀusion 2 (8%)
Clotted haemothorax 1 (4%)
Table 3 Comparison between volumes of ﬂuid drained before
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Figure 1 Outcome deﬁnitions of the studied patients.
Table 4 Total doses of streptokinase used in the studied
patients.
Group Total dose
Range (IU) Mean + SD
Successful group (15) 1,250,000–3,000,000 1,650,000 + 35,232.5
Failure and partially
successful group (10)
250,000–1,250,000 525,000 + 7.313
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Three groups were deﬁned regarding the study outcome:
Failure: Chest X-ray scoring 0, and chest ultrasound scor-
ing 0.
Partially successful: Chest X-ray scoring 1 or 2 and chest
ultrasound scoring 1.
Successful: Chest X-ray scoring 3 or 4, and chest ultrasound
scoring 2 or 3.
Patients addressed as failure or partially successful were
transferred to cardiothoracic surgeon to select the suitable line
for surgical interference. While in successful group the inter-
costal tube is removed and patient is discharged to continue
their treatment according to the underlying etiology.
Complications assessment
Patients were assessed carefully for evidence of drug complica-
tions including fever, pain, allergic reaction, bleeding or hemo-
dynamic changes. Fever was deﬁned as a temperature greater
than 3800C, or one degree elevation over baseline in previously
febrile patients [5].
Statistical analysis
Categorical variables were described by number and percent
(No, %), where continuous variables were described by mean
and standard deviation (Mean, SD). T-test was used to com-
pare between volume drained before and after streptokinase
in studied patients. A two-tailed p< 0.05 was considered
statistically signiﬁcant. All analyses were performed with the
SPSS 20.0 software.
Results
25 patients were included in the study (16 males and 9 females)
with age ranging from 31 to 75 years and their descriptive data
are demonstrated in Table 1.
Regarding the underlying etiology in studied patients the
commonest cases we faced were empyema and parapneumonic
effusion and the least common was clotted haemothorax as
demonstrated in Table 2.
Table 3 shows that the amount of ﬂuid drained increased
after streptokinase by a mean value of 1061.6 and there is a sig-
niﬁcant statistical difference between drained ﬂuid before and
after instillation (p< 0.01).
The ﬁnal outcome of the studied patients was deﬁned based
on the scoring of changes in X-ray and ultrasound on dis-
charge. Patients were divided into successful, partially success-
ful and failure groups. 60% of cases were successful as seen in
Fig. 1.
In successful group the total used dose of streptokinase ran-
ged from 1,250,000 IU to 3,000,000 IU which is the maximum
dose we needed in our study (Table 4).
Sonographic echo features of pleural adhesions among dif-
ferent outcome groups are shown in Table 5. Chance of success
increases when the adhesions are ﬁne.










Fine adhesions 10 10 (100%) 0
Coarse adhesions 8 1 (14%) 7 (86%)
Mixed 7 4 (57%) 3 (43%)
Figure 2 Complications in studied patients (n= 25).
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sient chest pain and fever in a few patients, while the majority
recorded no complications Fig. 2.
Discussion
Tillet and Sherry ﬁrst introduced ﬁbrinolytic therapy in 1949
as a treatment for empyema and complicated parapneumonic
effusion. Fibrinolytic therapy was reintroduced by Bergh
et al. in 1977, using a more puriﬁed form of streptokinase.
Since then, there have been many studies which support the
use of ﬁbrinolytic agents in empyema and parapneumonic effu-
sion treatment. These agents may be a safer, easier and cost
effective option for managing pleural adhesions and locula-
tions [6]. This work is considered the ﬁrst study in Assiut
University Hospital about the therapeutic role of intrapleural
ﬁbrinolytics.
Our study included 25 patients presented by pleural effu-
sion with intrapleural adhesions as documented by chest
sonography. Their ages ranged from 31 to 75 years with the
mean of 54.4 + 13.4. More than half of the studied patients
were males (64% vs 36% females). In spite of the small number
of patients included in our study, the commonest cases we
faced were empyema and parapneumonic effusion (64%).
This was comparable with Abu-Daff et al. in 2012 who used
intrapleural ﬁbrinolytics in 237 patients with loculated pleural
effusion and about 68% of the cases were empyema and com-
plicated parapneumonic effusion [6].
Regarding the amount of ﬂuid drained before and after
streptokinase instillation, our study reported marked differ-
ence between the two values with a mean value of 1061.6 with
a signiﬁcant statistical difference (P< 0.001).However, assess-
ment of the response to intrapleural streptokinase in this work
was based mainly on the changes that happened and detectedin both chest X-ray and ultrasound after completing the course
of therapy and on discharge. According to this rule, success
(complete adhesiolysis) was recorded in 60% of cases and par-
tial success in 24% while the procedure failed in 16% of cases.
The percentage of success in our study (60%) was nearly
similar to that reported by Temes et al.,1996 (61%) and
approximate to that recorded by Taylor et al. in 1994
(67%).However, our success rate was lower than that seen in
studies by Sanchez et al. in 1996 (92%) and Diacon et al. in
2004 (82%) [7–10]. We cannot exactly explain this variation
in success rate, however experience, selection of cases and
the parameters used to assess success; all may play a role.
In our work, sonographic examination was not only a help-
ful diagnostic tool but also it was valuable in predicting the
patient outcome according to the echo features of pleural
septa. In this study, we found that the chance of success was
high when the adhesions or septa were ﬁne. Previously, Chen
et al. in 2000 use the sonographic septation as a useful prog-
nostic indicator of acute thoracic empyema [11].
No major adverse effects were noted during application of
the treatment protocol. Transient chest pain and fever were the
only recorded complications in our study in a few patients.
Taylor et al. in 1994 reported that all patients tolerated
intrapleural streptokinase well; only one complained of
mild chest discomfort shortly after each streptokinase
instillation [8].
Conclusion and recommendation
We conclude that intrapleural streptokinase therapy may be
considered in septated pleural effusion as a safe and effective
treatment; it may obviate the need for surgery. Also, the ultra-
sound echo features of adhesions could be considered as a pre-
dictor for the response. Further trials using streptokinase and
other ﬁbrinolytic agents are recommended with a large number
of patients (preferably multicenter controlled trials).References
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